HERA - ECDC visit 09-02-2022

Helena Jirincova



Specific Objective ID		
1	Automation of preparation of sequencing libraries	
Process Indicate	or(s)	Target value
Publish call for te tender)	ender – 2 pipetting NGS robotic machines (conditional	1 💮
Publish call for ter	nder - 1 archiving system (conditional tender)	1
Acquisitions of the	e 2 pipetting NGS robotic machines	2
Acquisitions and in	nstallation of the archiving system	1
Connection of Omics Genomic laboratory to the NGS SARS-CoV-2 reporting system (ISIN).		1
Set up and verification of the standard operation procedure (SOP) of NGS library preparation and archiving system.		2
Operator admission and staff training		2
Output Indicator(s)		Target value
D1.1: Two installed pipetting automats, validated protocols and standard operation procedure (SOP) for NGS library preparation (Delivery in month 5)		1
D1.2: Archiving system (AS) is verified and connected to LIS data, the records/samples are accessible and AS enables easy storage and retrieval of archived samples. (Delivery in month 8)		1
Outcome/Impact Indicator(s)		Target value
Reaching the wee	kly sequencing capacity	376
SARS-CoV-2 seque	ences stored in GISAID (expected 5% failure)	2 800
Archives of SARS-	CoV-2 samples, viral strains, standards, primers	15 000

Delayed, but resolved – fully automatisation of most of the procedures (except of quantification, no integration possible)

D.1.1

- FoS CU manual /automated sequencing capacity -100 samples per 2 weeks
- Biomek 4000 Automated Liquid Handler with integrated PCR cycler Applied Biosystem
- installed, validation of the process finished
- NEB protocol v 3, without quantification and normalisation
- 2. NIPH NRL manual sequencing capacity 50 samples per week
- Biomek i5 4000 Automated Liquid Handler with integrated PCR cycler Analytics Jena
- 10-03-2022 instalation
- PCR cycler will by delivered in the end of Match
- Integration in manufacturer site succesfull
- NGS protocol setup preparedaccording to pippeting scheme
- CleanPlex® SARS-CoV-2 Panel Paragon Genomics
- Mass Array protocol setup prepared (obj 4)


D.1.2

3. Archive:

- Structure prepared based on: Open Access
- Hardware on site
- Architecture prepared



Pippeting scheme – NGS: Clean Plex protocol (Paragon Genomics)



Manual procedure NGS: 2 x 8 to 10 hours + Illumina (20 hours) – 3 days, last day in week - Wednesday

Another rented NGS machine (non HERA): Genexus: 32 samples/25 hours – in validation phase - fully automated procedure

Archive – structure of DB D.1.2

- Primary db <u>clinical material connected to LIS</u>
- Secondary db RNA/DNA
- Secondary db <u>Isolated viral strains</u>
 - dependent on primary db recent strains
 - Independent on primary db and LIS: old archive of strains (from 1957 2021) independent on primary db
- Secondary db Virtual db of strains/clinical material/RNA/DNA transferred to external institution
- Terciary db optionally conected to LIS
 - Standards- viral strains: inhouse/outsorced
 - Standards cell lines
 - Standards RNA/DNA/oligo
- Terciary db db in house primers/probes



Specific Objective ID	[2.2.2] Specific Objective Title and Description		
2	Capacities for sequence data storage and management		
Process Indicate	Process Indicator(s)		get value
Publish call for a t	Publish call for a tender		\odot
Purchase of the server (50TB NAS with a raid-6 array)		1	
Data and services transferred from the transitional storage at ELIXIR-CZ/CESNET		5 000	genomes
Output Indicator(s)		Tar	get value
D2.1: Installed and operating server (Delivery in month 6)		1	
Outcome/Impact Indicator(s)		Tar	get value
Stored individual data		7 000	genomes


Biosecurity

Agreement with users – ongoing - acceptance form (under preparation with layer)



Specific Objective ID	[2.2.3] Specific Objective Title and Description	
3	Establishing of bioinformatics pipelines for semi-automat data	ic analysis of WGS
Process Indicate	or(s)	Target value
Preparation and v	erification of pipeline for NGS data retrieval	1 😊
Development of a	lgorithms for automatic NGS data analysis	4
Development of a	lgorithms for merging of NGS data and metadata	1
Output Indicator(s)		Target value
D3.1: Scripts for metadata retrieving and data analysis (Delivery in month 8)		8
D3.2: Scripts for NGS data and metadata retrieving and analyses, followed by the merge assembled into workflow (Delivery in month 9)		9
D3.3: Public health data reports summarizing spread and frequency of SARS-CoV-V2 variants and mutations in the Czech Republic for policy making authorities (Delivery in month 12)		25
Outcome/Impact Indicator(s)		Target value
Infrastructure set up for NGS data assembled into the automatic workflow with a clear outcome for the public health authority		1









Objective 3 – Python script

covid-xls2dasta





https://github.com/Seraff/xls2dasta

Specific Objective ID	[2.2.4] Specific Objective Title and Description	
4	Enhancing the capacity of a rapid variant detection system by monitoring a large set of mutations by a method involving a combination of RT-PCR and MassARRAY analysis	
Process Indicate	or(s)	Target value
Publish a call for tender: 3 pieces of PCR-MassARRAY system (MALDI TOF technology based) - open system adopted to the detection at least 36 mutations in two end point PCR amplicons		1
Acquisitions of the 3 PCR- <u>MassARRAY</u> system (MALDI TOF technology based) - open system		3
Instruments' installation and staff training		3
Adaptation and verification of standard operation procedure for sample analysis		1
Output Indicator(s)		Target value
D4.1: Verified SOP for sample analysis (Delivery in month 5)		1
D4.2: Report on analyzed samples (min 10 000) (Delivery month 11)		1
Outcome/Impact Indicator(s)		Target value
Reaching minimal weekly operational capacity for sample analyses		1 500

Installation – 2 to 5 days Training - 2 to 3 days Validation - ongoing

NIPH NRL - 1st week in March

ZU OVA - 2nd week in March

ZU UnL - 3nd week in March

Capacity: 380 samples/week per machine 37 AA changes (SNIPs)

Mass Array library 8 – 10 hours target segment PCR -SAP-extension PCR Mass Array analysis 3 to 5 hours (depending of the amount of sample) Run – maximum of 94 samples (C19)



Specific Objective ID	[2.2.5] Specific Objective Title and	
5	Perform a retrospective analysis of samples from of the SARS-CoV-2 epidemic in the Czech Republic	n critical phases
Process Indicate	or(s)	Target value
Selection of archiv	ved samples for sequencing	4 000
Selection of laboratories involved in the NSSS with capacity to sequence		3
Output Indicator(s)		Target value
D5.1: Report on sequences of samples uploaded in GISAID (included 3 800 samples, expected 5% failure) (Delivery in month 11)		1
D5.2: Report characterizing diversity of SARS-CoV-2 and its development in time during the autumn-spring 2020/21 waves in the Czech Republic (Delivery in month 13)		1
Outcome/Impact Indicator(s)		Target value
Science based evidence of virus evolution under specified circumstances as a base for the future policy making decision and definition of public health strategies.		1

Specific Objective ID	[2.2.6] Specific Objective Title and Description	
6	Perform a population survey in 2021/2022 in order to determine the degree of subthreshold spread of the virus in the population and critical elements enabling mitigation.	
Process Indicate	or(s)	Target value
Selection of inclus	ion criteria for target population	1
Creating a question	onnaire	1
Distributing the sa	ample collection kits and questionnaires	100 000
Analysis of returned samples for SARS-CoV-2		Max 20 000
Output Indicator(s)		Target value
D6.1: Report on percentage of positive samples (expected return rate of 20 %) (Delivery in month 5)		1
D6.2: Report on sequences of samples uploaded in GISAID (included 500 samples, expected 5% failure) (Delivery in month 6)		1
D6.3: Report characterizing diversity of SARS-CoV-2 within targeted population the Czech Republic (Delivery in month 12)		1
Outcome/Impact Indicator(s)		Target value
Updated tools for the surveillance of SARS-CoV-2, influenza and respiratory viruses based on self-sampling of targeted population as a base for the future policy making decision and definition of public health strategies.		1

Objective 5 and 6

Obj 5 - retrospective WGS analysis



- during the drop of covid 19 cases
 - May to August
- Obj 6 prospective WGS study
 - Ongoing
 - Connected to Czech serological study PREVAL2



Obj 6 – Preval questionaire

Jméno a příjmení:		
Datum odběru:		
L. Pohlaví □Muž □Žena 2. Státní příslušnost □ ČR □.	lná, uveďte Jaká	
3. Výška: cm Váha : kg		
i. Kouříte? □ NE □ ANO → kolík cigaret denně kouříte □ Bývalý kuřák → Uva	dte, kolik let jste k	ouřil(a)
5. Měl (a) jste pozitivní PCR test na COVID-19?		
□ ne Jednou rok: měsíc:	vního PCR testu)	
5. Jak veliká je vaše domácnost?		
_ Žiji sám _ Žiji s 1-4 lidml →		
NE ☐ ANO → uvedte jaké (<i>je možné zoškrtnout více odpovědí.</i>) ☐ teplota > 37,0°C ☐ kašěl ☐ bole: ☐ obtížné dýchání ☐ ztráta chutí nebo číchu ☐ Jiné 8. Byl jste očkován proti viru SARS-CoV-2? ☐ NE ☐ ANO → pokud ano, pokračujte s otázkami níže	st v krku	
 Objevily se u vás nežádoucí stavy po očkování? ☐ NE ☐ ANO → prosím upřesn 	ěte (Je mažné zaški	tnaut vice
odpovědí.):	po 1. dávce	po 2. dávce
 reakce v místě vpichu (bolest, zarudnutí, otok, svědění, zduření apod.) 		
 celkové příznaky (horečka, zimnice, únava, slabost, pocit horka apod. alerzická reakce (kopřívka, ekzém, otok obličeje apod.) 	000000	H
bolest hlavy, závrať, spavost, mravenčení, křeče apod.	_	=
 bolest svalů, kloubů, šlach, zad, ztuhnutí šíje apod. 		
 nevolnost, zvracení, průjem, plynatost apod. dušnost, kačel zrvchlené dúchání, holest v krku, kruácení z nosu anod. 		=
 dušnost, kašel, zrychlené dýchání, bolest v krku, krvácení z nosu apod. Jiné 	ä	0 0 0 0 0
10. Prosím upřesněte rekonvalescenci po nežádoucím stavu po očkování:		
 po 1. dávce: ☐ bez omezení ☐ klidový režim doma do 2 dnů bez lékaře ☐ klidový režim doma nad 2 dny bez lékaře ☐ návštěva léka 	fa 🗆 hoenitalizaca	
po 2. dávce: ☐ bez omezení ☐ klidový režim doma do 2 dnů bez lékaře	C nospitalizate	
□ klidový režim doma nad 2 dny bez lékaře □ návštěva léka	fe 🗌 hospitalizace	
,,,		




Specific Objective ID	[2.2.8] Specific Objective Title and Description	
7	Develop infrastructure to facilitate the timely reporting of genotype data to ECDC and other supra-national institutions, and the sharing of data in the public domain	
Process Indicate	or(s)	Target value
Standardizing of procedure for data mining from central public health databases (ISIN) and diagnostic laboratories		1
Setup the workflow to analyze population wide distribution of genotypes in the Czech Republic		1
Implementation of reporting workflow to incorporate virus genotype data from Czech Republic into ECDC and GISAID EpiCoV		1 per week
Output Indicator(s)		Target value
D7.1: SOP for the data mining from public health sector databases (Delivery in month 9)		1
D7.2: Reports published in public domain of ECDC and GISAID <u>EpiCoV</u> including genotype data (Delivery in month 12)		5
Outcome/Impact Indicator(s)		Target value
Enhanced surveillance capability and capacity to contribute to the international database with timely and actual data for future policy making and definition of public health strategies at the EU level.		1

- Data pipeline scheme
- Script for the definition of representative sample – WGS
- Data acces to Nationa register of covid data and infectious diseased data – still under negotiation
- Acces via export of several metadata sets – very slow



Obj 7 – data pipeline



Specific Objective ID	[2.2.9] Specific Objective Title and Description		
8	Increasing the professional capacity of laboratory experts and epidemiologists, deepening interdisciplinary cooperation between institutions with different specializations		
Process Indicate	or(s)	Target value	
Organization of the individual consultations and participation at the laboratory meetings		100	
Organization of the interdisciplinary webinars for epidemiologist and diagnostic laboratories on good practices in data reporting of SARS-CoV-2, and methodology of their interpretation (target number of participants – 200)		10	
Publication of training materials online, via project website		10	
Output Indicator(s)		Target value	
	n individual consultations, laboratory meetings ebinars (Delivery in month 10)	1	
Outcome/Impact Indicator(s)		Target value	
Operational interdisciplinary network of laboratory and public health experts across the Czech Republic		1	

1x sequencing worshop

experiences from Czech sequenation centers

Sequencing meetings – monthly base


One day conference for epidemiologist and laboratories - interdisciplinary


3 lectures for the bioinformatics - beginners in


- NGS data interpretation
- NGS principle
- NGS raw data assembly
- AA structure
- Haplotype analyses



Thank you for your attention







Zdroj: virus.img.cas.cz





Project "Enhancing Whole Genome Sequencing (WGS) and/or Reverse Transcription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the Covid-19 pandemic in the European Union and European Economic Area" had received funding from the European Centre for Disease Prevention and Control under the Grant Agreement number ECDC/HERA/2021/004 ECD.12218.



More information about the project: http://www.szu.cz/ecdc-1

NOTE:

Information included reflects only the authors' view and the Centre (ECDC) is not responsible for any use that may be made of the information it contains.